Evidence map›Paper›PMID 41846930›Full record

ArticleFrontiers in immunology2026

Efficacy analysis of iptacopan in a patient with thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: a case report.

Zixuan Zhao, Lin Guo, Jiao Ge, Wei Wu, Yanhua Yue, Yan Qiu, Feng Li, Wenxi Hua, Weiying Gu, Yan Lin

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zixuan Zhao *Department of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Lin Guo *Department of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Jiao GeDepartment of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Wei WuDepartment of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Yanhua YueDepartment of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Yan QiuDepartment of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Feng LiDepartment of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Wenxi HuaDepartment of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Weiying GuDepartment of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Yan LinDepartment of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the efficacy of Iptacopan in transplantation-associated thrombotic microangiopathy (TA-TMA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), we report the case of a 43-year-old male with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR, with IDH1 and STAG2 mutations) who developed TA-TMA after allo-HSCT. The patient had an initial partial response to the C5 inhibitor eculizumab, but the disease progressed. Oral Iptacopan (200 mg twice daily) was initiated on Day +36. The patient received a total of six sessions of therapeutic plasma exchange and two concurrent doses of defibrotide during the Iptacopan course. After 30 days of Iptacopan treatment, the patient exhibited a significant hematological response, evidenced by a reduction in LDH (758 U/L to 357 U/L), a rise in platelets (17 to 43×10

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteThrombotic MicroangiopathiesAdultBenzoatesHumansIndolesMalePiperidinesPlasma ExchangeTransplantation, HomologousTreatment OutcomeBenzoatesIndolesiptacopanPiperidinesallo-HSCTAMLfactor B inhibitoriptacopanTA-TMA

Identifiers

PMID41846930
PMCPMC12989387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.